The tweet was deleted by the author.
But we saved everything 🙂.
Ocugen, Inc. participated in this year’s Clinical Trials at the Summit, where its Chairman, CEO, and Co-Founder Dr. Shankar Musunuri joined a panel of industry leaders to address inherited retinal diseases (IRDs) and the need to advance innovative gene therapies.
The event brought together key stakeholders in the biotech sector, emphasizing the critical role of new approaches in treating complex genetic disorders. Ocugen, Inc. continues to prioritize development in gene therapy to address unmet medical needs in ophthalmology.
Ocugen, Inc. is advancing gene therapy candidates targeting ophthalmic diseases lacking approved treatments. The company is pursuing early-stage gene therapy for 100,000 Stargardt disease patients, who currently have no FDA approved options, with OCU410ST showing early promise. Ocugen is also moving OCU400 toward regulatory filing as a potential one-time treatment for retinitis pigmentosa.